214 related articles for article (PubMed ID: 11549802)
1. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia.
Brouard MC; Prins C; Mach-Pascual S; Saurat JH
Dermatology; 2001; 203(1):57-9. PubMed ID: 11549802
[TBL] [Abstract][Full Text] [Related]
2. Stevens-Johnson syndrome after treatment with STI571: a case report.
Hsiao LT; Chung HM; Lin JT; Chiou TJ; Liu JH; Fan FS; Wang WS; Yen CC; Chen PM
Br J Haematol; 2002 Jun; 117(3):620-2. PubMed ID: 12028031
[TBL] [Abstract][Full Text] [Related]
3. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia.
Gambillara E; Laffitte E; Widmer N; Decosterd LA; Duchosal MA; Kovacsovics T; Panizzon RG
Dermatology; 2005; 211(4):363-5. PubMed ID: 16286749
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous reactions to STI571.
Brouard M; Saurat JH
N Engl J Med; 2001 Aug; 345(8):618-9. PubMed ID: 11529225
[No Abstract] [Full Text] [Related]
5. Pityriasis rosea associated with imatinib (STI571, Gleevec).
Konstantopoulos K; Papadogianni A; Dimopoulou M; Kourelis C; Meletis J
Dermatology; 2002; 205(2):172-3. PubMed ID: 12218236
[TBL] [Abstract][Full Text] [Related]
6. Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia.
Kuwano Y; Asahina A; Watanabe R; Fujimoto M; Ihn H; Tamaki K
Int J Dermatol; 2006 Oct; 45(10):1249-51. PubMed ID: 17040457
[No Abstract] [Full Text] [Related]
7. A patient of chronic myelogenous leukemia developing painful rash on feet.
Kumar P; Das NK; Sil A; Chakrabarti P
J Postgrad Med; 2012; 58(4):331-4. PubMed ID: 23298941
[No Abstract] [Full Text] [Related]
8. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Schwarz M; Kreuzer KA; Baskaynak G; Dörken B; le Coutre P
Eur J Haematol; 2002 Oct; 69(4):254-6. PubMed ID: 12431246
[TBL] [Abstract][Full Text] [Related]
9. [Drug reaction with eosinophilia and systemic symptoms (DRESS) following imatinib therapy].
Le Nouail P; Viseux V; Chaby G; Billet A; Denoeux JP; Lok C
Ann Dermatol Venereol; 2006; 133(8-9 Pt 1):686-8. PubMed ID: 17053739
[TBL] [Abstract][Full Text] [Related]
10. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
[TBL] [Abstract][Full Text] [Related]
11. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
Valeyrie L; Bastuji-Garin S; Revuz J; Bachot N; Wechsler J; Berthaud P; Tulliez M; Giraudier S
J Am Acad Dermatol; 2003 Feb; 48(2):201-6. PubMed ID: 12582389
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Pou M; Saval N; Vera M; Saurina A; Solé M; Cervantes F; Botey A
Leuk Lymphoma; 2003 Jul; 44(7):1239-41. PubMed ID: 12916879
[TBL] [Abstract][Full Text] [Related]
13. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate-induced pseudoporphyria in two children.
Mahon C; Purvis D; Laughton S; Bradbeer P; Teague L
Pediatr Dermatol; 2014; 31(5):603-7. PubMed ID: 24920470
[TBL] [Abstract][Full Text] [Related]
15. Successful progressive challenge after a cutaneous reaction to imatinib mesylate (Gleevec): a case report and review of the literature.
Park MA; Volcheck GW; Guarderas JC
Allergy Asthma Proc; 2004; 25(5):345-7. PubMed ID: 15603208
[TBL] [Abstract][Full Text] [Related]
16. Indications for imatinib mesylate therapy and clinical management.
Guilhot F
Oncologist; 2004; 9(3):271-81. PubMed ID: 15169982
[TBL] [Abstract][Full Text] [Related]
17. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
Drummond A; Micallef-Eynaud P; Douglas WS; Hay I; Holyoake TL; Drummond MW
Br J Haematol; 2003 Mar; 120(5):911-3. PubMed ID: 12614232
[No Abstract] [Full Text] [Related]
18. Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate.
Rousselot P; Larghero J; Raffoux E; Calvo F; Tulliez M; Giraudier S; Rybojad M
Br J Haematol; 2003 Mar; 120(6):1091-2. PubMed ID: 12648085
[No Abstract] [Full Text] [Related]
19. Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate.
Arora B; Kumar L; Sharma A; Wadhwa J; Kochupillai V
Ann Oncol; 2004 Feb; 15(2):358-9. PubMed ID: 14760137
[No Abstract] [Full Text] [Related]
20. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia.
Scott AD; Lee M; Kubba F; Chu A
Clin Exp Dermatol; 2015 Dec; 40(8):926-7. PubMed ID: 25266712
[No Abstract] [Full Text] [Related]
[Next] [New Search]
